Tag #Neurodegenerative Disease

Showing 13 to 24 of 30 results

cnn.com

🌐 85% Global Worthiness

May 8, 01:17

High Ultra-Processed Food Intake Linked to Increased Parkinson's Disease Risk

A study of nearly 43,000 participants found that consuming 11 or more servings of ultra-processed foods daily is associated with a 2.5 times greater likelihood of experiencing multiple early-stage Parkinson's symptoms compared to those eating only three servings; the findings suggest potential preve...

High Ultra-Processed Food Intake Linked to Increased Parkinson's Disease Risk

A study of nearly 43,000 participants found that consuming 11 or more servings of ultra-processed foods daily is associated with a 2.5 times greater likelihood of experiencing multiple early-stage Parkinson's symptoms compared to those eating only three servings; the findings suggest potential preve...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this study's methodology and the type of data collected contribute to its findings regarding the link between ultra-processed foods and Parkinson's disease?

This research, involving nearly 43,000 participants over 26 years, links high ultra-processed food consumption to an increased risk of prodromal Parkinson's symptoms. The study points towards potential mechanisms like reduced micronutrients, increased inflammation, and gut microbiome disruption as contributing factors. These findings highlight the dietary component's role in neurodegenerative disease.

bbc.com

🌐 85% Global Worthiness

Apr 16, 10:08

Northern Scotland's High Huntington's Disease Rate Prompts Call for Action

A new study shows Northern Scotland has a Huntington's disease rate of 14.5 per 100,000 people—over five times the global average—with over 160 adults in the region genetically predisposed but untested, prompting calls for improved care planning.

Northern Scotland's High Huntington's Disease Rate Prompts Call for Action

A new study shows Northern Scotland has a Huntington's disease rate of 14.5 per 100,000 people—over five times the global average—with over 160 adults in the region genetically predisposed but untested, prompting calls for improved care planning.

Progress

4% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this study's methodology differ from previous research, and what additional insights does it provide regarding the scope of the problem?

The study's use of family tree records, unlike previous statistical models, provides a more precise count of those at risk. This precise data is crucial for planning healthcare services and future treatments. The high rate necessitates immediate action for resource allocation and care planning.

repubblica.it

🌐 85% Global Worthiness

Apr 9, 10:13

Saliva Test Distinguishes Lewy Body Dementia from Alzheimer's and Parkinson's

Researchers at Roma Tre University discovered two salivary biomarkers—alpha-synuclein and phosphorylated tau protein—that distinguish Lewy body dementia from Alzheimer's and Parkinson's, impacting 200,000 undiagnosed Italians.

Saliva Test Distinguishes Lewy Body Dementia from Alzheimer's and Parkinson's

Researchers at Roma Tre University discovered two salivary biomarkers—alpha-synuclein and phosphorylated tau protein—that distinguish Lewy body dementia from Alzheimer's and Parkinson's, impacting 200,000 undiagnosed Italians.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings of the Roma Tre University study on Lewy body dementia, and how will this impact diagnosis and treatment?

Researchers at Roma Tre University discovered two salivary biomarkers—alpha-synuclein and phosphorylated tau protein—that can distinguish Lewy body dementia (LBD) from Alzheimer's and Parkinson's diseases. This discovery simplifies LBD diagnosis, enabling earlier and more effective treatment for the estimated 200,000 undiagnosed LBD sufferers in Italy.

arabic.euronews.com

🌐 75% Global Worthiness

Mar 22, 10:09

Eight-Year Gantenerumab Treatment Shows Promise in Delaying Alzheimer's Onset

A small clinical trial of 22 genetically predisposed individuals showed that eight years of treatment with gantenerumab reduced their risk of developing Alzheimer's symptoms by half; however, the drug was later discontinued due to inefficacy in larger trials.

Eight-Year Gantenerumab Treatment Shows Promise in Delaying Alzheimer's Onset

A small clinical trial of 22 genetically predisposed individuals showed that eight years of treatment with gantenerumab reduced their risk of developing Alzheimer's symptoms by half; however, the drug was later discontinued due to inefficacy in larger trials.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the limitations of this study, and what further research is needed to validate these findings?

The study, published in The Lancet Neurology, indicates that preventative treatment with anti-amyloid antibodies may need to be administered for several years before symptoms appear to be effective. While promising, the results are considered preliminary due to the small sample size and the fact that gantenerumab is less effective than other available anti-amyloid treatments.

elmundo.es

🌐 85% Global Worthiness

Mar 6, 07:11

Parkinson's Disease Cases to Double by 2050, Driven by Aging Population

A study published in the British Medical Journal projects that 25.2 million people will live with Parkinson's disease globally by 2050, more than double the number in 2021, primarily due to the aging population and increased life expectancy; the highest increases are expected in East Asian countries...

Parkinson's Disease Cases to Double by 2050, Driven by Aging Population

A study published in the British Medical Journal projects that 25.2 million people will live with Parkinson's disease globally by 2050, more than double the number in 2021, primarily due to the aging population and increased life expectancy; the highest increases are expected in East Asian countries...

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key global implications of the projected 25.2 million Parkinson's disease cases by 2050?

By 2050, Parkinson's disease cases are projected to more than double globally, reaching 25.2 million individuals, primarily due to the aging population. This significant increase, detailed in a British Medical Journal study, highlights a growing public health challenge, with the highest increases anticipated in East Asian countries, men, and middle-income nations.

abcnews.go.com

🌐 85% Global Worthiness

Feb 5, 22:13

Spinal Cord Stimulation Improves Muscle Function in SMA Patients

A small study shows spinal cord stimulation temporarily improved muscle function in three adults with spinal muscular atrophy (SMA), offering hope for a new treatment for this progressive, incurable disease.

Spinal Cord Stimulation Improves Muscle Function in SMA Patients

A small study shows spinal cord stimulation temporarily improved muscle function in three adults with spinal muscular atrophy (SMA), offering hope for a new treatment for this progressive, incurable disease.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate impacts of spinal cord stimulation on SMA patients' motor function and mobility?

In a groundbreaking pilot study, three adults with spinal muscular atrophy (SMA) experienced improved muscle function and mobility after receiving spinal cord stimulation. The implanted device temporarily restored some muscle function, enabling participants to walk farther and stand more easily. This is the first evidence suggesting that this technology, already tested for paralysis, might also benefit neurodegenerative diseases.

forbes.com

🌐 85% Global Worthiness

Apr 23, 01:14

Parkinson's Disease: Impact, Causes, and Future Directions

Parkinson's disease, a progressive neurodegenerative disorder affecting over one million Americans, is marked by a loss of dopamine-producing nerve cells causing motor and non-motor symptoms; while genetic factors play a minor role, environmental toxins are strongly implicated, and men are 1.5 times...

Parkinson's Disease: Impact, Causes, and Future Directions

Parkinson's disease, a progressive neurodegenerative disorder affecting over one million Americans, is marked by a loss of dopamine-producing nerve cells causing motor and non-motor symptoms; while genetic factors play a minor role, environmental toxins are strongly implicated, and men are 1.5 times...

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the known and suspected causes of Parkinson's disease, and how do these factors contribute to its prevalence and impact?

Parkinson's disease, the second most common neurodegenerative disease after Alzheimer's, is characterized by the loss of dopamine-producing nerve cells. While genetic factors play a role (less than 20 percent of cases), environmental toxins like pesticides and TCE are strongly linked to its onset, suggesting a multifactorial etiology. Gender also plays a significant role, with men being 1.5 times more likely to develop the disease than women.

dw.com

🌐 85% Global Worthiness

Apr 16, 04:09

EU Approves Lecanemab for Early-Stage Alzheimer's; Strict Criteria Apply

The European Commission approved Lecanemab, a new Alzheimer's drug targeting amyloid plaques, for patients with minimal cognitive impairment and low ApoE4 gene copies; it offers a five-month delay in cognitive decline but is restricted due to potential side effects.

EU Approves Lecanemab for Early-Stage Alzheimer's; Strict Criteria Apply

The European Commission approved Lecanemab, a new Alzheimer's drug targeting amyloid plaques, for patients with minimal cognitive impairment and low ApoE4 gene copies; it offers a five-month delay in cognitive decline but is restricted due to potential side effects.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of the European Commission's approval of Lecanemab for Alzheimer's treatment?

The European Commission approved Lecanemab, a monoclonal antibody, to treat early-stage Alzheimer's. Unlike previous treatments, it targets the disease itself by reducing amyloid plaques, not just symptoms. However, its use is restricted to patients with minimal cognitive impairment and only one or zero copies of the ApoE4 gene to minimize risks of serious side effects.

elmundo.es

🌐 85% Global Worthiness

Mar 31, 19:14

New Biomarker Predicts Alzheimer's Cognitive Decline

Researchers at Stanford University have discovered a new biomarker—a ratio of two synaptic proteins (YWHAG and NPTX2)—that accurately predicts cognitive decline in Alzheimer's disease, potentially improving early diagnosis and treatment selection.

New Biomarker Predicts Alzheimer's Cognitive Decline

Researchers at Stanford University have discovered a new biomarker—a ratio of two synaptic proteins (YWHAG and NPTX2)—that accurately predicts cognitive decline in Alzheimer's disease, potentially improving early diagnosis and treatment selection.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the researchers identify this biomarker, and what factors were considered in their analysis?

The research, involving nearly 3,400 individuals across six cohorts, utilized machine learning to analyze proteomic data from cerebrospinal fluid and brain tissue. A higher ratio of YWHAG to NPTX2 correlated with increased dementia risk, regardless of amyloid or tau levels. This finding addresses a critical gap in current diagnostic tools, which lack predictive power.

tr.euronews.com

🌐 85% Global Worthiness

Mar 6, 10:10

Parkinson's Disease Cases to More Than Double by 2050

A new study predicts that the global burden of Parkinson's disease will more than double by 2050, reaching 25.2 million cases due to increased life expectancy and population growth, with East Asia projected to have the highest number of cases.

Parkinson's Disease Cases to More Than Double by 2050

A new study predicts that the global burden of Parkinson's disease will more than double by 2050, reaching 25.2 million cases due to increased life expectancy and population growth, with East Asia projected to have the highest number of cases.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do geographic variations in Parkinson's prevalence relate to socioeconomic factors, lifestyle choices, and environmental exposures?

The study highlights geographic disparities, with lower- and middle-income countries experiencing the sharpest rise. Factors contributing to the increase include decreased physical activity in developed nations, environmental toxins (air pollution, pesticides, microplastics), and socioeconomic factors. These findings underscore the urgent need for new treatments and enhanced social support.

elmundo.es

🌐 85% Global Worthiness

Feb 16, 19:09

Alzheimer's: A Personal and Scientific Perspective

Sandeep Jauhar's "The Brain of My Father" chronicles his father's struggle with Alzheimer's, revealing the devastating effects on individuals, families, and healthcare systems, and highlighting the need for improved treatments and societal understanding.

Alzheimer's: A Personal and Scientific Perspective

Sandeep Jauhar's "The Brain of My Father" chronicles his father's struggle with Alzheimer's, revealing the devastating effects on individuals, families, and healthcare systems, and highlighting the need for improved treatments and societal understanding.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the global impact of Alzheimer's disease, and how does it affect families and healthcare systems?

Alzheimer's disease affects over 45 million people globally, with nearly 800,000 cases in Spain alone. This number multiplies when considering the impact on families, who often become invisible victims. The author's personal experience, detailed in his book "The Brain of My Father," highlights the devastating effects on both the patient and their loved ones.

dw.com

🌐 75% Global Worthiness

Feb 5, 16:14

Spinal Cord Implant Shows Promise for ALS Treatment

A spinal cord implant significantly improved muscle strength and mobility in three ALS patients, showing promise for a new treatment approach to this incurable genetic disease, according to a small, one-month pilot study published in Nature Medicine.

Spinal Cord Implant Shows Promise for ALS Treatment

A spinal cord implant significantly improved muscle strength and mobility in three ALS patients, showing promise for a new treatment approach to this incurable genetic disease, according to a small, one-month pilot study published in Nature Medicine.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate impacts of spinal cord stimulation on ALS patients' motor function, based on this study?

A spinal cord implant improved muscle strength and mobility in three adults with amyotrophic lateral sclerosis (ALS), a debilitating genetic disease. The implant delivered controlled electrical impulses, resulting in increased walking distance and the ability to stand from a kneeling position for one participant who was previously unable to do so. This is the first evidence suggesting that spinal stimulation could also help with neurodegenerative diseases.

Showing 13 to 24 of 30 results